|
Company optimizes PSP94 assay and develops Vitronectin assay in urine
Miraculins Inc., a medical diagnostic company focused on developing and commercializing diagnostic tests for unmet clinical needs, is pleased to update the market on its assay development progress for PSP94 and Vitronectin, the two proteins which comprise the Company’s P2V™ prostate cancer test.
Read More
|
|
Mount Sinai Services to Acquire ASR Materials to Detect Miraculins’ Biomarkers
Miraculins Inc., a medical diagnostic company focused on developing and commercializing diagnostic tests for unmet clinical needs is pleased to announce that it has signed a letter of intent with Mount Sinai Services (“MSS”) which would allow MSS to acquire FDA regulated commercial products known as Analyte Specific Reagents (“ASRs”) in order to develop in house clinical tests for Miraculins’ growing pipeline of biomarkers.
Read More
|
|
Miraculins Inc., a medical diagnostic company focused on developing and commercializing diagnostic tests for unmet clinical needs, announces that the Board of Directors has granted 500,000 options at an exercise price of $0.15 per share to Mr. Christopher Moreau, President and CEO, in accordance with the Company’s stock option plan. The options are subject to regulatory approval
Read More
|
|
Internal Review Confirms Set of Compelling Markers Including a Single Marker With 72% Sensitivity at 95% Specificity Miraculins Inc. a medical diagnostic company focused on developing and commercializing diagnostic tests for unmet clinical needs, is pleased to announce that it has completed the internal review of its gastric cancer program and has confirmed seven blood based protein biomarkers of interest for their potential to separate gastric cancer patients from non-gastric cancer patients. This includes a single marker that performs with a 72% sensitivity at 95% specificity (AUC=0.925) known as MIR-GP1. Based on this promising result, the Company plans to advance this program by identifying these markers through protein purification and amino acid sequencing, beginning with MIR-GP1.
Read More
|
|
Company develops functioning prototype assay for detecting PSP94 in urine Miraculins Inc., a medical diagnostic company focused on developing and commercializing diagnostic tests for unmet clinical needs, is pleased to announce that the Company has completed development of a prototype assay for PSP94 (Prostate Secretory Protein) on the Luminex Bio-Plex 200 Protein Array System and plans to manufacture and begin selling PSP94 based test kits for research purposes by the end of 2008. As previously disclosed by Miraculins, PSP94 plays a significant role in the Company’s P2V™ panel test that is currently being internally developed.
Read More
|
|
|